27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL. 3 key findings →
Participants: 286 Evidence: high
Full summary, score breakdown and related studies → Original source
The aim of this international guideline on dementia was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with dementia. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The overall PAF for dementia in Denmark was 37·8% (95% CI 35·6-40·0) for the assessed risk factors. 4 key findings →
Design: cohort Participants: 1,753,515 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The quality of included studies with only a few longitudinal studies, limits the conclusions which may be drawn from the present findings especially regarding the biomarkers other than hippocampal volume. 4 key findings →
Design: systematic review Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The study will explore the added value of a multifaceted intervention programme and contribute to the design of future interventions for patients with mild dementia and their caregivers. 1 key finding →
Participants: 330 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Treatment success in Alzheimer disease (AD) trials is generally based on benefits over placebo-treated controls. 2 key findings →
Participants: 3,403 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The findings do not support an effect of the exercise intervention on a single measure of neurodegeneration in AD. 2 key findings →
Participants: 136 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
When poor SRH was present we found no increased risk for NH placement or death among elderly people with mild AD. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
From a prospective Memory Clinic cohort including consecutively referred patients, age 60 years or above, and with MMSE score 20 or above, 36 patients with AD and 30 with MCI were included in this study. 4 key findings →
Participants: 36 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia is under-diagnosed to a greater extent among ethnic minorities in the age group 60 years and older but is over-diagnosed in the age group younger than 60 years. 3 key findings →
Participants: 219 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Physical exercise may have some effect on cognition in patients with Alzheimer disease (AD). 4 key findings →
Participants: 53 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Costs of care in patient with AD are high and related to dementia severity as well as presence of behavioural disturbances. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study we investigated impaired awareness of cognitive deficits in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In addition, we examined whether anosognosia had an impact on the agreement between patient and informant ratings of QoL and whether anosognosia, dementia severity, depression and behavioural symptoms were significantly correlated to QoL in early AD. 4 key findings →
Participants: 48 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Ethnic minority patients are seen on a regular basis in European dementia clinics. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
It is estimated that approximately 40,000 people in Denmark suffer from Alzheimer's disease (AD), a neurodegenerative dementia. 4 key findings →
Participants: 40,000 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →